They found that young women had more aggressive tumor biology, poorer outcomes, and more frequent discordance between conventional markers (e.g., Ki67) and genomic risk scores; for instance, 50% of women ≤ 40 with Ki67 < 10% were classified as high-risk by the PAM50 risk-of-relapse (ROR) score, whereas <5% of older women showed that discordance. This evidence concerns the gene MKI67 and neoplasm.